Aman Chauhan, MD
Medical Oncology · San Francisco, CANPI 1902193147
Payments from drug & device makers
Across 311 payments — averaging $16,568 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$2.5M
- Novartis$1.2M
- Alkermes, Inc.$1.1M
- Clovis Oncology, Inc.$127K
- E.r. Squibb & Sons, L.L.C.$78K
- Tersera Therapeutics LLC$66K
- plus $160K from 14 others
Across 5 payments — averaging $3240.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$16K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 61 | $2,458,827 |
| Novartis | 21 | $1,209,097 |
| Alkermes, Inc. | 73 | $1,054,319 |
| Clovis Oncology, Inc. | 4 | $127,000 |
| E.r. Squibb & Sons, L.L.C. | 5 | $77,872 |
| Tersera Therapeutics LLC | 16 | $65,609 |
| Amgen | 3 | $53,873 |
| Exelixis Inc. | 43 | $28,784 |
| Y-mabs Therapeutics, Inc. | 6 | $19,670 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 37 | $14,130 |
| Curium US LLC | 12 | $11,899 |
| Ipsen Biopharmaceuticals, Inc | 10 | $10,855 |
| Lexicon Pharmaceuticals, Inc. | 8 | $7,574 |
| Sanofi | 3 | $4,143 |
| Lantheus Medical Imaging, Inc. | 2 | $2,880 |
| Advanced Accelerator Applications | 1 | $2,500 |
| Jazz Pharmaceuticals Inc. | 1 | $1,590 |
| Boehringer Ingelheim International GmbH | 2 | $1,425 |
| Ipsen Innovation | 2 | $474 |
| Cardinal Health 414 LLC | 1 | $22 |
How this compares
$5,152,543 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in San Francisco
- Kevin KimSan Francisco$10.8M
- Amy ChienSan Francisco$10.5M
- Stephen SherwinSan Francisco$6.9M
- Chloe AtreyaSan Francisco$5.7M
- Emily BergslandSan Francisco$3.4M
- Bridget KeenanSan Francisco$2.2M
- Sarmad SadeghiLos Angeles$26.1M
- Marwan FakihDuarte$24.2M
- Sumanta PalDuarte$15.9M
- Farshid DayyaniOrange$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.